Phytoestrogens as cardioprotective agents

Cardiology in Review

Volumn 13, Issue 1, 2005, Pages 13-17

  Park, Denise ^a   Huang, Tiffany ^b   Frishman, William H ^c,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Coronary artery disease; Daidzein; Genistein; Isoflavones; Phytoestrogens

Indexed keywords

ANTILIPEMIC AGENT; BIOCHANIN A; DAIDZEIN; ENTEROLACTONE; ESTROGEN; FORMONONETIN; GENISTEIN; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; PHYTOESTROGEN; PROGESTERONE; RESVERATROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL REACTIVITY; BREAST CANCER; BREAST TENDERNESS; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHICKPEA; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MECHANISM; EDEMA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LEGUME; LIVER METABOLISM; NAUSEA; REVIEW; SOYBEAN; THROMBOGENESIS; TREATMENT CONTRAINDICATION; UTERUS CANCER;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FABACEAE; FEMALE; HUMANS; ISOFLAVONES; LIPOPROTEINS; PHYTOESTROGENS; PLANT EXTRACTS;

EID: 13444310823     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000126084.68791.32     Document Type: Review

References (67)

1. Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med. 2001;161:1161-1172.
2. Bennetts HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust Vet J. 1975;22:2-12.
3. Thompson LU, Robb P, Serraino M, et al. Mammalian lignan production from various foods. Nutr Cancer. 1991;16:43-52.
4. Hertog MG, Kronhout D, Aravonis C, et al. Flavanoid intake and long-tern risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995;155:381-386.
5. Adlercruetz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin. J Steroid Biochem. 1987;27:1135-1144.
6. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131:1362S-1375S.
7. Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2, 289 deaths in 15 years. Prev Med. 1984;13:141-154.
8. Food labeling: health claims; soy protein and coronary heart disease; Food and Drug Administration, HHS: final rule. Fed Regis. 1999;64:57700-57733.
9. Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem. 1995;22:181-187.
10. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
11. Lichtenstein AH, Jalbert SM, Adlercreutz H, et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2002;22:1852-8.
12. Sanders TA, Dean TS, Grainger D, et al. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr. 2002;76:373-377.
13. Squadrito F, Altavilla D, Marabito N, et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis. 2002;163:339-347.
14. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr. 2002;21:97-102.
15. Gardner CD, Newell KA, Cherin R, et al. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am J Clin Nutr. 2001;73:728-735.
16. Hermansen K, Sondergaard M, Hoie L, et al. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care. 2001;24:228-233.
17. Wangen KE, Duncan AM, Xu X, et al. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic post-menopausal women. Am J Clin Nutr. 2001;73:225-231.
18. Howes JB, Sullivan D, Lai N, et al. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis. 2000;152:143-147.
19. Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol. 2000;85:1297-1301.
20. Dewell A, Hollenbeck CB, Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab. 2002;87:118-121.
21. Goodman-Gruen D, Kritz-Silverstein D. Usual Dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. 2001;131:1202-1206.
22. Sirtori CR, Lovati MR, Manzoni C, et al. Soy and cholesterol reduction: clinical experience. J Nutr 1995;125:598S-605S.
23. Borradaile NM, de Dreu LE, Wilcox LJ, et al. Soy phytoestrogens, genistein and daidzein decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem J. 2002;366(Pt 2):531-539.
24. Hirose N, Inoue T, Nishihara K, et al. Inhibition of cholesterol absorption and synthesis in rats by sesamin. J Lipid Res. 1991;32:629-638.
25. Adams MR, Golden DL, Register TC, et al. The atheroprotective effect of dietary soy isoflavones in apolipoprotein E-/- mice requires the presence of estrogen receptor-alpha. Arterioscler Thromb Vasc Biol. 2002;22:1859-1864.
26. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863-870.
27. Tikkanen MJ, Wähälä K, Ojala S, et al. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A. 1998;95:3106-3110.
28. Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentration and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr. 2000;72:395-400.
29. Exner M, Hermann M, Hofbauer R, et al. Genistein prevents the glucose autoxidation mediated atherogenic modification of low density lipoprotein. Free Radic Res. 2001;34:101-112.
30. Raines EW, Ross R. Biology of atherosclerotic plaque formation: possible role of growth factors in lesion development and the potential impact of soy. J Nutr. 1995;125:624S-630S.
31. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr. 1995;125:790-797.
32. Takahashi M, Ikeda U, Masuyama JI, et al. Monocyte-endothelial cell interaction induces expression of adhesion molecules on human umbilical cord endothelial cells. Cardiovasc Res. 1996;32:422-429.
33. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5595.
34. Kondo K, Suzuki Y, Ikeda Y, et al. Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation. Eur J Pharmacol. 2002;455:53-57.
35. Dobrydneva Y, Williams RL, Morris GZ, et al. Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc Pharmacol. 2002;40:399-410.
36. Honoré EK, Williams JK, Anthony MS, et al. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril. 1997;67:148-154.
37. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab. 2001;86:3053-3060.
38. March JD. Phytoestrogens and vascular therapy (editorial comment). J Am Coll Cardiol. 2000;35:1986-1987.
39. van der Schouw YT, Pijpe A, Lebrun CEI, et al. Higher usual dietary intake of phytoestrogens is associated with lower aortic stiffness in post-menopausal women. Arteriscler Thromb Vasc Biol. 2002;22:1316-1322.
40. Figtree GA, Griffiths H, Lu Y-A, et al. Plant-derived estrogens relax coronary arteries in vivo by a calcium antagonistic mechanism. J Am Coll Cardiol 2000;35:1977-1985.
41. Nevala R, Korpela R, Vapaatalo H. Plant derived estrogens relax rat mesenteric artery in vivo. Life Sci. 1998;63:95-100.
42. Karamsetty MR, Klinger JR, Hill NS. Phytoestrogens restore nitric oxide-mediated relaxation in isolated pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Ther. 2001;297:968-974.
43. Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to concentration of enterolactone: a prospective population-based case-control study. Lancet. 1999;354:2112-2115.
44. Lucas EA, Wild RD, Hammond LJ, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002;87:1527-1532.
45. Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol. 2000;9:220-225.
46. Vanharanta M, Voutilainen S, Nurmi T, et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis. 2002;160:465-469.
47. Fang JG, Lu M, Chen ZH, et al. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry. 2002;8:4191-4198.
48. Bhat KPL, Kosmeder JW II, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3:1041-1064.
49. Olas B, Wachowiz B, Saluk-Juszczak J, et al. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res. 2002;107:141-145.
50. Gehm BD, Mc Andrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997;94:14138-14143.
51. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652-1658.
52. Tsunoda N, Pomeroy S, Nestel P. Absorption in humans of isoflavones from soy and red clover is similar. J Nutr. 2002;132:2199-201.
53. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999;84:895-898.
54. Clifton-Bligh PB, Baber RJ, Fulcher GR, et al. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause. 2001;8:259-265.
55. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of soy isoflavone: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002;76:1126-1137.
56. Libby P. Inflammation is atherosclerosis. Nature. 2002;420:868-874.
57. Weis M, Schlichting CL, Engleman EG, et al. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler Thromb Vasc Biol. 2002;22:1817-1823.
58. Jenkins DJA, Kendall CWC, Connelly PW, et al. Effects of high- and low-isoflavone (Phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism. 2002;51:919-924.
59. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:717-722.
60. Hulley S, Furberg C, Barrett-Connor E, et al. for the HERS Research Group. Noncardiovascular disease outcomes during 6/8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288:58-66.
61. Peterson HB, Thacker SB, Corso PS, et al. Hormone therapy: making decisions in the face of uncertainty. Arch Intern Med. 2004;164:2308-2311.
62. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study. JAMA. 2002;288:980-987.
63. Hays J, Ockene JK, Brunner RL, et al. for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.
64. Wassertheil-Smoller S, Hendrix S, Limacher M, et al for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
65. Albertazzi P, Purdic D. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas. 2002;42:173.
66. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for treatment of hot flashes: the Isoflavone Clover Extract (ICE) study. A randomized controlled trial. JAMA. 2003;290:207-214.
67. Frishman WH, Gomberg-Maitland M, Freeman R, et al. Hormones as cardiovascular drugs: estrogens, progestin, thyroxine, growth hormone, corticosteroids and testosterone. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York: McGraw Hill, 2003:617-654.